Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5648649 | 0.94 | TDP1 (0.42) | TDP1HDAC6CNR1POLBKMT2A | |
| SCHEMBL5647169 | 0.94 | TDP1 (0.44) | TDP1CTRB1HDAC6CNR1POLB | |
| SCHEMBL5647852 | 0.90 | HDAC6 (0.41) | TDP1HDAC6CNR1POLBKMT2A | |
| SCHEMBL5652588 | 0.89 | PTPN1 (0.44) | TDP1HDAC6CNR1POLBKMT2A | |
| SCHEMBL5645726 | 0.85 | KMT2A (0.44) | TDP1HDAC6CNR1POLBKMT2A | |
| SCHEMBL5647390 | 0.84 | TDP1 (0.47) | TDP1CTRB1HDAC6CNR1POLB | |
| SCHEMBL5650848 | 0.80 | CTRB1 (0.39) | CTRB1KMT2A | |
| SCHEMBL5652364 | 0.80 | CTRB1 (0.39) | CTRB1HDAC6KMT2A | |
| SCHEMBL5645672 | 0.78 | HDAC6 (0.46) | TDP1CTRB1HDAC6KMT2A | |
| SCHEMBL5648643 | 0.78 | TDP1 (0.47) | TDP1HDAC6CNR1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7199146-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-04-03 | — | — | US | disclosed |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | US | disclosed |
| US-7053112-B2 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-05-30 | — | — | US | disclosed |
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122073-A1 | Imidazolidinedione analogs useful as anticoagulants and antihrombotics | SERPINC1, F2, BDKRB1 | TDP1 1348/4885CTRB1 259/4885HDAC6 172/4885 |
| US-20060142363-A1 | Imidazolidinedione analogs useful as anticoagulants and antithrombotics | SERPINC1, F2, BDKRB1 | TDP1 1027/4885CTRB1 208/4885HDAC6 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.